Marcus Schmitt-Egenolf (M Schmitt-Egenolf)

ResearcherID Scopus Author ID Loop profile ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 29

Top Venues

The British journal of dermatology

Annals of medicine

Journal of clinical medicine

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Umeå Universitet Medicinska fakulteten

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Umeå Universitet Medicinska fakulteten Jan 01 2014

Sweden

Professor :: Dermatology

Publications

Jenny M Norlin, Sofia Löfvendahl, Marcus Schmitt-Egenolf
Health-related quality of life in patients with generalized pustular psoriasis - a Swedish register study. Annals of medicine 56 (1) (2024)
Jenny M Norlin, Sofia Löfvendahl, Marcus Schmitt-Egenolf
Health-related quality of life in patients with palmoplantar pustulosis - a Swedish register study. Annals of medicine 56 (1) (2024)
Jenny M Norlin, Sofia Löfvendahl, Marcus Schmitt-Egenolf
Health-related quality of life in patients with palmoplantar pustulosis - a Swedish register study. Annals of medicine 56 (1) (2024)
Jenny M Norlin, Sofia Löfvendahl, Marcus Schmitt-Egenolf
Health-related quality of life in patients with generalized pustular psoriasis - a Swedish register study. Annals of medicine 56 (1) (2024)
Jenny M Norlin, Sofia Löfvendahl, Marcus Schmitt-Egenolf
Health-related quality of life in patients with generalized pustular psoriasis - a Swedish register study. Annals of medicine 56 (1) (2024)
Jenny M Norlin, Sofia Löfvendahl, Marcus Schmitt-Egenolf
Health-related quality of life in patients with palmoplantar pustulosis - a Swedish register study. Annals of medicine 56 (1) (2024)
Marcus Schmitt-Egenolf
The Disruptive Force of Real-World Evidence. Journal of clinical medicine 12 (12) (2023)
Marcus Schmitt-Egenolf
The Disruptive Force of Real-World Evidence. Journal of clinical medicine 12 (12) (2023)
Sofia Löfvendahl, Jenny M Norlin, Marcus Schmitt-Egenolf
Comorbidities in palmoplantar pustulosis: a Swedish population-based register study. The British journal of dermatology (2023)
Jenny M Norlin, Sofia Löfvendahl, Marcus Schmitt-Egenolf
The Influence of Socioeconomic Factors on Access to Biologics in Psoriasis. Journal of clinical medicine 12 (23) (2023)
Helena Tufvesson Stiller, Marcus Schmitt-Egenolf, Helena Fohlin, Srinivas Uppugunduri
Patient reported experiences of Swedish patients being investigated for cancer during the Covid-19 pandemic. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 31 (7) (2023)
Kirk Geale, Marcus Schmitt-Egenolf
Severity of psoriasis: time to disentangle severity from symptom control. The British journal of dermatology 186 (6) (2022)
Sofia Löfvendahl, Jenny M Norlin, Marcus Schmitt-Egenolf
Prevalence and incidence of generalized pustular psoriasis in Sweden: a population-based register study. The British journal of dermatology 186 (6) (2022)
Sofia Löfvendahl, Jenny M Norlin, Marcus Schmitt-Egenolf
Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study. Psoriasis (Auckland, N.Z.) 12 (2022)
Alejandro Arana, Jesper Hallas, Josephina G Kuiper, Helen Booth, Johan Reutfors, Brian Calingaert, Lars Christian Lund, Elizabeth Crellin, Marcus Schmitt-Egenolf, James A Kaye, Karin Gembert, Kenneth J Rothman, Helle Kieler, Daniel Dedman, Eline Houben, Lia Gutiérrez, Nina Sahlertz Kristiansen, Susanna Perez-Gutthann
Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clinical epidemiology 13 (2021)
Marcus Schmitt-Egenolf, Jonatan Freilich, Natalia M Stelmaszuk-Zadykowicz, Eydna Apol, Jes B Hansen, Lars-Åke Levin
Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study. Dermatology and therapy 11 (6) (2021)
Sofia Löfvendahl, Jenny M Norlin, Marcus Schmitt-Egenolf
Prevalence and incidence of palmoplantar pustulosis in Sweden: a population-based register study. The British journal of dermatology 185 (5) (2021)
Marcus Schmitt-Egenolf
Complete skin clearance and beyond. The British journal of dermatology 184 (1) (2020)
Gabriella Bröms, Helle Kieler, Anders Ekbom, Gissler Mika, Karin Hellgren, Maarit K Leinonen, Lars Pedersen, Marcus Schmitt-Egenolf, Henrik Toft Sorensen, Fredrik Granath
Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy. Alimentary pharmacology & therapeutics 52 (5) (2020)
Gabriella Bröms, Helle Kieler, Anders Ekbom, Gissler Mika, Karin Hellgren, Anna-Maria Lahesmaa-Korpinen, Lars Pedersen, Marcus Schmitt-Egenolf, Henrik Toft Sorensen, Fredrik Granath
Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiology and drug safety 29 (3) (2020)
Helena Tufvesson Stiller, Rasmus Mikiver, Srinivas Uppugunduri, C Lindholm, E Månsson Brahme, Marcus Schmitt-Egenolf
Health-related quality of life in patients with melanoma - characterization of a Swedish cohort. The British journal of dermatology 182 (2) (2019)
Jenny M Norlin, Kristoffer Nilsson, U Persson, Marcus Schmitt-Egenolf
Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals. The British journal of dermatology 182 (4) (2019)
Frida Hjalte, Katarina Steen Carlsson, Marcus Schmitt-Egenolf
Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register. The British journal of dermatology 178 (1) (2018)
David Hägg, Anders Sundström, Marie Eriksson, Marcus Schmitt-Egenolf
Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. American journal of clinical dermatology 18 (4) (2018)
Marcus Schmitt-Egenolf
What can we learn from 'dropouts' in clinical trials? The British journal of dermatology 178 (2) (2018)
Paul S Calara, Rikard Althin, Katarina Steen Carlsson, Marcus Schmitt-Egenolf
Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 31 (1) (2017)
Jenny M Norlin, Paul Samuel Calara, U Persson, Marcus Schmitt-Egenolf
Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy. The Journal of dermatological treatment 28 (6) (2017)
Jenny M Norlin, Katarina Steen Carlsson, Ulf Persson, Marcus Schmitt-Egenolf
Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 29 (6) (2016)
Paul S Calara, Jenny M Norlin, Rikard Althin, Katarina Steen Carlsson, Marcus Schmitt-Egenolf
Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 30 (2) (2016)

Marcus Schmitt-Egenolf.css-eqlu8i{font-size:small;padding-left:4px;} (M Schmitt-Egenolf)

Publication Activity (10 Years)

Top Topics

Top Venues

Marcus Schmitt-Egenolf (M Schmitt-Egenolf)